Skip to content

Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection

Efficacy of Bispectral Index Monitoring for Midazolam and Meperidine Induced Sedation During Endoscopic Submucosal Dissection

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01157598
Enrollment
56
Registered
2010-07-07
Start date
2009-09-30
Completion date
Unknown
Last updated
2010-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Adenoma, Gastric Cancer

Keywords

gastric adenoma, early gastric cancer

Brief summary

Background: Endoscopic submucosal dissection (ESD) usually requires adequate level of sedation due to lengthy and uncomfortable procedure. Propofol induced sedation with bispectral index (BIS) monitoring has been reported to lead to higher satisfaction of patients and endoscopists during ESD. However, there is no data about efficacy of midazolam and meperidine induced sedation with BIS monitoring during ESD. This study was to evaluate whether midazolam and meperidine induced sedation with BIS monitoring could improve the satisfaction and reduce the dose of midazolam and meperidine during ESD.

Interventions

parameter monitoring of bispectral index

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* gastric adenomas, differentiated-type gastric cancers greater than 30 mm in diameter without ulceration and gastric cancers up to 30 mm with ulceration, or minute submucosal invasion

Exclusion criteria

* if they were under 18 years of age * had an ASA classification of 4-5 * were pregnant * had a history of stroke or an allergy to sedative drugs.

Design outcomes

Primary

MeasureTime frame
the satisfaction of patients and endoscopist in midazolam and meperidine induced sedation with BIS monitoring during ESDwithin the one day after ESD

Secondary

MeasureTime frame
the dose of midazolam and meperidine during ESD with BIS monitoringwithin one hour after ESD

Countries

South Korea

Contacts

Primary ContactJae.J Kim, professor
jjkim@skku.edu+82-2-3410-3409
Backup ContactKi Joo Kang, Dr
kj74.kang@samsung.com+82-2-3410-3409

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026